The Protective Effect of L-arginine in Cisplatin-induced Nephrotoxicity in Streptozotocin-induced Diabetic Rats

Gharibi, Fatemeh; Soltani, Nepton; Maleki, Maryam; Talebi, Ardeshir; Nasiri, Masoumeh; Shirdavani, Soheyla; Nematbakhsh, Mehdi

The Protective Effect of L-arginine in Cisplatin-induced Nephrotoxicity in Streptozotocin-induced Diabetic Rats

Document Type : Original Article

Authors

¹ Water and Electrolytes Research Center, Isfahan University of Medical Sciences, Isfahan; Department of Physiology, Isfahan University of Medical Sciences, Isfahan, Iran

² Molecular Medicine Research Center, Hormozgan University of Medical Sciences, Bandar Abbas; Department of Physiology, Hormozgan University of Medical Sciences, Bandar Abbas, Iran

³ Water and Electrolytes Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

⁴ Clinical Pathology, Isfahan University of Medical Sciences, Isfahan, Iran

⁵ Water and Electrolytes Research Center, Isfahan University of Medical Sciences, Isfahan; Department of Physiology, Isfahan University of Medical Sciences, Isfahan; Isfahan MN Institute of Basic and Applied Sciences Research, Isfahan, Iran

Abstract

Background: Cisplatin (CP) is accompanied with a nephrotoxicity. L-arginine (LA) plays an important role in the regulation of renal function. The present study was designed to investigate the protective role of LA supplementation in CP-induced nephrotoxicity in a diabetic rat's model. Materials and Methods: Sixteen adult female and male Wistar rats were used and they received a single dose of streptozotocin (STZ) (60 mg/kg i.p.). Diabetic female and male rats were arranged as groups 1–5 and groups 6–10, respectively. Groups 1 and 6 (LA groups) received LA alone. Groups 2 and 7 (CP groups) received CP alone. Groups 3 and 8 (CP + LA [PT] groups) received LA as prophylaxis and then treated with LA and CP. Groups 4 and 9 (CP + LA [T] groups) were treated with LA and CP simultaneously. Groups 5 and 10 (CP + LA [P] groups) received LA as prophylaxis and then treated with CP. Results: The serum creatinine (Cr) level of males in Groups 8 and 9 was significantly increased when compared with LA and CP (P < 0.05), whereas no differences were observed in Cr level in female groups. Blood urea nitrogen/Cr ratio and kidney weight were reduced in all CP-receiving male rats. Such observation was not seen in female rats. Different results related to weight loss were obtained between male and female animals. The kidney tissue damage score in CP + LA (PT) male group was significantly greater than CP group (P < 0.05). Conclusion: Our findings indicate that administration of LA in female and male rats has no protective effect on the severity of nephrotoxicity induced by CP in diabetic rats.

Keywords

References

1.	Cherla G, Jaimes EA. Role of L-arginine in the pathogenesis and treatment of renal disease. J Nutr 2004;134 10 Suppl: 2801S-6S.
2.	Saleh S, El-Demerdash E. Protective effects of L-arginine against cisplatin-induced renal oxidative stress and toxicity: Role of nitric oxide. Basic Clin Pharmacol Toxicol 2005;97:91-7.
3.	Palm F, Friederich M, Carlsson PO, Hansell P, Teerlink T, Liss P. Reduced nitric oxide in diabetic kidneys due to increased hepatic arginine metabolism: Implications for renomedullary oxygen availability. Am J Physiol Renal Physiol 2008;294:F30-7.
4.	Ghosh S, Khazaei M, Moien-Afshari F, Ang LS, Granville DJ, Verchere CB, et al. Moderate exercise attenuates caspase-3 activity, oxidative stress, and inhibits progression of diabetic renal disease in db/db mice. Am J Physiol Renal Physiol 2009;296:F700-8.
5.	Hall GC, Roberts CM, Boulis M, Mo J, MacRae KD. Diabetes and the risk of lung cancer. Diabetes Care 2005;28:590-4.
6.	Moien-Afshari F, Ghosh S, Elmi S, Khazaei M, Rahman MM, Sallam N, et al. Exercise restores coronary vascular function independent of myogenic tone or hyperglycemic status in db/db mice. Am J Physiol Heart Circ Physiol 2008;295:H1470-80.
7.	Arany I, Safirstein RL, editors. Cisplatin Nephrotoxicity. Seminars in Nephrology. 2003; 23(5): 460-464.
8.	Miller RP, Tadagavadi RK, Ramesh G, Reeves WB. Mechanisms of cisplatin nephrotoxicity. Toxins (Basel) 2010;2:2490-518.
9.	Yao X, Panichpisal K, Kurtzman N, Nugent K. Cisplatin nephrotoxicity: A review. Am J Med Sci 2007;334:115-24.
10.	Nematbakhsh M, Sorooshzadeh SM, Pezeshki Z, Talebi A, Ashrafi F. Gender difference in the serum levels of total nitric oxide metabolites, nitrite, and nitrate in cisplatin-induced nephrotoxicity in rats. J Isfahan Med Sch 2013;30:818-821.
11.	Saad SY, Najjar TA, Daba MH, Al-Rikabi AC. Inhibition of nitric oxide synthase aggravates cisplatin-induced nephrotoxicity: Effect of 2-amino-4-methylpyridine. Chemotherapy 2002;48:309-15.
12.	Naghizadeh H, Banparvari M, Salehikia A. Effect of one course exercise with consumption Vitamin E on antioxidant status and cardiovascular risk factors. Zahedan J Res Med Sci 2010;12 (1): 33-39.
13.	Mount PF, Power DA. Nitric oxide in the kidney: Functions and regulation of synthesis. Acta Physiol (Oxf) 2006;187:433-46.
14.	Bidadkosh A, Derakhshanfar A, Rastegar AM, Yazdani S. Antioxidant preserving effects of L-arginine at reducing the hemodynamic toxicity of gentamicin-induced rat nephrotoxicity: Pathological and biochemical findings. Comp Clin Pathol 2012;21:1739-44.
15.	Haghighi M, Nematbakhsh M, Talebi A, Nasri H, Ashrafi F, Roshanaei K, et al. The role of angiotensin II receptor 1 (AT1) blockade in cisplatin-induced nephrotoxicity in rats: Gender-related differences. Ren Fail 2012;34:1046-51.
16.	Aleisa AM, Al-Majed AA, Al-Yahya AA, Al-Rejaie SS, Bakheet SA, Al-Shabanah OA, et al. Reversal of cisplatin-induced carnitine deficiency and energy starvation by propionyl-L-carnitine in rat kidney tissues. Clin Exp Pharmacol Physiol 2007;34:1252-9.
17.	Moghadamnia AA, Hakiminia S, Baradaran M, Kazemi S, Ashrafpour M. Vitamin D improves learning and memory impairment in streptozotocin-induced diabetic mice. Arch Iran Med 2015;18:362-6.
18.	Yang C, Fei Y, Qin Y, Luo D, Yang S, Kou X, et al. Bacterial flora changes in conjunctiva of rats with streptozotocin-induced type I diabetes. PLoS One 2015;10:e0133021.
19.	Eshraghi-Jazi F, Nematbakhsh M, Nasri H, Talebi A, Haghighi M, Pezeshki Z, et al. The protective role of endogenous nitric oxide donor (L-arginine) in cisplatin-induced nephrotoxicity: Gender related differences in rat model. J Res Med Sci 2011;16:1389-96.
20.	Soltani N, Nematbakhsh M, Eshraghi-Jazi F, Talebi A, Ashrafi F. Effect of oral administration of magnesium on cisplatin-induced nephrotoxicity in normal and streptozocin-induced diabetic rats. Nephrourol Mon 2013;5:884-90.
21.	Jilanchi S, Nematbakhsh M, Mazaheri S, Talebi A, Zolfaghari B, Pezeshki Z, et al. Pomegranate flower extract does not prevent cisplatin-induced nephrotoxicity in female rats. Int J Prev Med 2014;5:1621-5.
22.	Wang H, Jia Z, Sun J, Xu L, Zhao B, Yu K, et al. Nitrooleic acid protects against cisplatin nephropathy: Role of COX-2/mPGES-1/PGE2 cascade. Mediators Inflamm 2015;2015:293474.
23.	Sarangarajan R, Cacini W. Early onset of cisplatin-induced nephrotoxicity in streptozotocin-diabetic rats treated with insulin. Basic Clin Pharmacol Toxicol 2004;95:66-71.
24.	Grover B, Buckley D, Buckley AR, Cacini W. Reduced expression of organic cation transporters rOCT1 and rOCT2 in experimental diabetes. J Pharmacol Exp Ther 2004;308:949-56.
25.	Santoso JT, Lucci JA 3^rd, Coleman RL, Schafer I, Hannigan EV. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: A randomized trial. Cancer Chemother Pharmacol 2003;52:13-8.
26.	Pabla N, Dong Z. Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies. Kidney Int 2008;73:994-1007.
27.	Beladi Mousavi SS, Hossainzadeh M, Khanzadeh A, Hayati F, Beladi Mousavi M, Zeraati AA, et al. Protective effect of forced hydration with isotonic saline, potassium chloride and magnesium sulfate on cisplatin nephrotoxicity: An initial evaluation. Asia Pac J Med Toxicol 2013;2:136-9.
28.	Claybaugh T, Decker S, McCall K, Slyvka Y, Steimle J, Wood A, et al. L-arginine supplementation in type II diabetic rats preserves renal function and improves insulin sensitivity by altering the nitric oxide pathway. Int J Endocrinol 2014;2014:171546.
29.	Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: A meta-analysis. Int J Cancer 2007;121:856-62.
30.	Wu G, Bazer FW, Davis TA, Kim SW, Li P, Marc Rhoads J, et al. Arginine metabolism and nutrition in growth, health and disease. Amino Acids 2009;37:153-68.
31.	Ortiz MC, Albertoni Borghese MF, Balonga SE, Lavagna A, Filipuzzi AL, Elesgaray R, et al. Renal response to L-arginine in diabetic rats. A possible link between nitric oxide system and aquaporin-2. PLoS One 2014;9:e104923.
32.	Asna N, Lewy H, Ashkenazi IE, Deutsch V, Peretz H, Inbar M, et al. Time dependent protection of amifostine from renal and hematopoietic cisplatin induced toxicity. Life Sci 2005;76:1825-34.
33.	Morris SM Jr., Gao T, Cooper TK, Kepka-Lenhart D, Awad AS. Arginase-2 mediates diabetic renal injury. Diabetes 2011;60:3015-22.
34.	Yegin SÇ, Yur F, Çetin S, Güder A. Effect of lycopene on serum nitrite-nitrate levels in diabetic rats. Indian J Pharm Sci 2015;77:357-60. [PUBMED] [Full text]
35.	Yao L, Kobori H, Rahman M, Seth DM, Shokoji T, Fan Y, et al. Olmesartan improves endothelin-induced hypertension and oxidative stress in rats. Hypertens Res 2004;27:493-500.
36.	Kamper M, Tsimpoukidi O, Chatzigeorgiou A, Lymberi M, Kamper EF. The antioxidant effect of angiotensin II receptor blocker, losartan, in streptozotocin-induced diabetic rats. Transl Res 2010;156:26-36.
37.	Jablecka A, Bogdanski P, Balcer N, Cieslewicz A, Skoluda A, Musialik K. The effect of oral L-arginine supplementation on fasting glucose, HbA1c, nitric oxide and total antioxidant status in diabetic patients with atherosclerotic peripheral arterial disease of lower extremities. Eur Rev Med Pharmacol Sci 2012;16:342-50.
38.	Tunctan B, Korkmaz B, Sari AN, Kacan M, Unsal D, Serin MS, et al. Contribution of iNOS/sGC/PKG pathway, COX-2, CYP4A1, and gp91(phox) to the protective effect of 5,14-HEDGE, a 20-HETE mimetic, against vasodilation, hypotension, tachycardia, and inflammation in a rat model of septic shock. Nitric Oxide 2013;33:18-41.
39.	Mohamadin AM, Hammad LN, El-Bab MF, Gawad HS. Can nitric oxide-generating compounds improve the oxidative stress response in experimentally diabetic rats? Clin Exp Pharmacol Physiol 2007;34:586-93.
40.	Si X, Li P, Zhang Y, Zhang Y, Lv W, Qi D. Renoprotective effects of olmesartan medoxomil on diabetic nephropathy in streptozotocin-induced diabetes in rats. Biomed Rep 2014;2:24-28.
41.	Ghanbari E, Nejati V, Azadbakht M. Protective effect of royal jelly against renal damage in streptozotocin induced diabetic rats. Iran J Toxicol 2015;9: 1258-1263
42.	Pezeshki Z, Nematbakhsh M, Mazaheri S, Eshraghi-Jazi F, Talebi A, Nasri H, et al. Estrogen abolishes protective effect of erythropoietin against cisplatin-induced nephrotoxicity in ovariectomized rats. ISRN Oncol 2012;2012:890310.
43.	Mohamed HE, El-Swefy SE, Mohamed RH, Ghanim AM. Effect of erythropoietin therapy on the progression of cisplatin induced renal injury in rats. Exp Toxicol Pathol 2013;65:197-203.

Advanced Biomedical Research